Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E25.60 EPS (ttm)4.12 Insider Own0.07% Shs Outstand1.60B Perf Week2.82%
Market Cap168.29B Forward P/E16.02 EPS next Y6.58 Insider Trans-37.44% Shs Float1.59B Perf Month8.18%
Income6.62B PEG1.68 EPS next Q1.44 Inst Own73.80% Short Float0.95% Perf Quarter9.66%
Sales27.27B P/S6.17 EPS this Y15.60% Inst Trans0.07% Short Ratio3.00 Perf Half Y42.58%
Book/sh4.19 P/B25.15 EPS next Y18.41% ROA9.90% Target Price102.50 Perf Year72.87%
Cash/sh5.98 P/C17.61 EPS next 5Y15.22% ROE118.50% 52W Range59.27 - 106.54 Perf YTD8.96%
Dividend2.84 P/FCF37.85 EPS past 5Y10.80% ROI18.00% 52W High-1.09% Beta1.54
Dividend %2.70% Quick Ratio1.30 Sales past 5Y8.00% Gross Margin76.50% 52W Low77.80% ATR1.79
Employees29000 Current Ratio1.50 Sales Q/Q8.80% Oper. Margin37.20% RSI (14)68.71 Volatility1.74% 1.72%
OptionableYes Debt/Eq5.65 EPS Q/Q4.40% Profit Margin24.30% Rel Volume0.99 Prev Close106.49
ShortableYes LT Debt/Eq5.08 EarningsJan 26 BMO Payout60.20% Avg Volume5.02M Price105.38
Recom2.30 SMA205.06% SMA508.09% SMA20030.15% Volume4,989,618 Change-1.04%
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jan-23-18 04:37PM  Novartis Announces Positive Results on Migraine Candidate Zacks
01:12PM  Vermont Legalizes Recreational Marijuana on January 22, 2018 Market Realist
12:48PM  3 Large Cap Pharma Stocks to Beat Earnings This Quarter Zacks
10:32AM  The Other Side of Legalizing Recreational Marijuana Market Realist
09:28AM  J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve Zacks
09:02AM  What a Country Could Gain from Legalizing Recreational Marijuana Market Realist
07:56AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck Zacks
07:33AM  The Marijuana Ecosystems Potential Business Opportunities Market Realist
07:31AM  Analyst Recommendations for Merck & Co. in January 2018 Market Realist
Jan-22-18 12:20PM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? InvestorPlace
11:11AM  Healthcare ETFs to Watch As Q4 Earnings Unfold Zacks
10:34AM  What's in the Cards for Varian Medical (VAR) in Q1 Earnings? Zacks
10:33AM  Is Investment in the Marijuana Space Picking Up? Market Realist
10:12AM  What's in the Cards for Novartis (NVS) This Earnings Season? Zacks
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
09:04AM  The Motivation for Recreational Marijuana Consumption Market Realist
08:47AM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? Zacks
07:37AM  Why the Medical Marijuana Industry Is Growing Market Realist
07:32AM  Merck & Co.s Cardiovascular and Immunology Products in 3Q17 Market Realist
Jan-21-18 09:08AM  5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them Motley Fool
Jan-19-18 05:20PM  How Marijuana Acceptance Is Evolving Globally Market Realist
04:39PM  Which Biotech Stocks Could Surprise To The Upside On Earnings? Investor's Business Daily
03:45PM  Must-Knows before Investing in the Marijuana Industry Market Realist
11:05AM  Johnson & Johnsons Pharmaceutical Segment: 4Q17 Estimates Market Realist
10:34AM  Amgen/Allergan's Avastin Biosimilar Secures EU Approval Zacks
08:43AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis Zacks
08:41AM  The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group Zacks
Jan-18-18 04:26PM  Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18? Zacks
04:17PM  Top Research Reports for Apple, JPMorgan & AbbVie Zacks
10:30AM  A Look into Amgens Collaborations in 2H17 Market Realist
09:26AM  J&J (JNJ) Hits New 52-Week High: What's Driving the Stock? Zacks
07:32AM  How Amgens Enbrel and Nplate Are Positioned for 2018 Market Realist
01:06AM  [$$] Buybacks, Pension Contributions and Savings: Companies Tout Tax Benefits The Wall Street Journal
Jan-17-18 08:32AM  Is Gilead Sciences, Inc. a Buy in 2018? Motley Fool
Jan-16-18 08:35AM  Novartis (NVS) Announces Acceptance of Humira BLA by the FDA Zacks
08:04AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Jan-15-18 09:04AM  How Investors Can Access the Marijuana Industry Market Realist
07:36AM  Why Canada May Be Legalizing Cannabis for Recreational Use This Year Market Realist
Jan-12-18 02:55PM  Gauging Marijuana Risk: The Potential Investment Blowback Market Realist
01:25PM  The Arrival of Marijuana Market Realist
11:54AM  Should You Jump on the Marijuana Bandwagon? Market Realist
10:00AM  2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better Motley Fool
08:00AM  AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call PR Newswire
07:00AM  3 of the Best Dividend Aristocrats for Retirement InvestorPlace
Jan-11-18 11:52AM  FDA Advisers Slam Lipocine's Testosterone Pill, Raising Doubts About 'Low T' Drugs Forbes
11:50AM  Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward Market Realist
10:17AM  Elagolix May Advance the Treatment Paradigm in Womens Health Market Realist
09:49AM  Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally InvestorPlace
08:00AM  Here's What AbbVie's Management Just Said About Its Future Motley Fool
07:34AM  How Ioniss Spinraza Performed in 3Q17 Market Realist
07:30AM  Miles White's Bold Moves Made Abbott Laboratories A Global Force Investor's Business Daily
06:04AM  7 Must-See Numbers From AbbVie's J. P. Morgan Presentation Motley Fool
03:00AM  Earnings Season Watch List: AbbVie Investor's Business Daily
Jan-10-18 10:33AM  AbbVies Rova-T: Can Label Expansion Make It a Blockbuster Drug? Market Realist
10:33AM  Analysts Recommendations for Incyte in January 2018 Market Realist
09:36AM  Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar Zacks
09:05AM  AbbVies Rova-T and the Treatment of Small Cell Lung Cancer Market Realist
09:00AM  Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology Market Realist
07:38AM  AbbVies Rova-T: Solid Growth Driver for the Future? Market Realist
07:31AM  AbbVies Position in the Growing Oncology Market in 2018 Market Realist
07:30AM  Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018 ACCESSWIRE
06:32AM  Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ) Motley Fool
Jan-09-18 05:15PM  AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio Market Realist
04:37PM  AbbVie's Upadacitinib Gains Breakthrough Therapy Designation Zacks
03:45PM  AbbVies Venclexta for Chronic Lymphocytic Leukemia Market Realist
02:10PM  AbbVie Expects Peak Sales of $7 Billion for Imbruvica Market Realist
02:03PM  Is AbbVie Stock Still A Strong Buy? Motley Fool
11:59AM  4 Best Marijuana Stocks to Play the Green Rush Zacks
11:54AM  AbbVie"s JAK1 Inhibitor Granted FDA"s Breakthrough Therapy
10:32AM  Why AbbVie Is Focused on Expanding Risankizumabs Label for Multiple Immunology Indications Market Realist
08:06AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Jan-08-18 07:00PM  Cramer's lightning round: Mercadolibre is even better tha... CNBC Videos
06:50PM  Cramer's lightning round: Mercadolibre is even better than eBay was CNBC
10:32AM  Understanding AbbVies Positive Upadacitinib Data for Atopic Dermatitis Market Realist
10:03AM  US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh Reuters
10:02AM  Galapagos Reports Topline Data From Osteoarthritis Study Zacks
09:03AM  Why AbbVies Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis Market Realist
08:00AM  AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis PR Newswire
07:35AM  What Upadacitinib Did for AbbVie in 2017 Market Realist
01:13AM  This Is Expected to Boost AbbVies Growth Prospects Market Realist
01:13AM  Why Humira Is Still a Solid Growth Driver for AbbVie in 2018 Market Realist
01:13AM  How Increasing Biologic Penetration Could Boost AbbVies Revenues Market Realist
Jan-07-18 09:09AM  5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers Motley Fool
07:00AM  2 Top Dividend Stocks to Buy in 2018 Motley Fool
Jan-05-18 07:20PM  Top 5 Biotech Stocks for 2018 Investopedia
03:10PM  Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017 Market Realist
02:39PM  Spiros Segalas Buys 3 New Stocks in 4th Quarter
01:40PM  Why AbbVie Is Expected to Report Robust Revenue Growth for 2017 Market Realist
12:07PM  AbbVie and Peers: Analyst Recommendations in December Market Realist
09:35AM  Will J&J (JNJ) Continue to Tread Growth Path This Year? Zacks
08:26AM  Key Biosimilar Approvals in 2017: Progress Report Zacks
Jan-04-18 06:28PM  3 Large-Cap Pharma Stocks to Watch Out for This New Year Zacks
10:49AM  Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports
10:33AM  Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018? Zacks
06:03AM  18 Reasons I Like Biotech Stocks in 2018 Motley Fool
Jan-03-18 06:45PM  Top 4 Marijuana Stocks to Watch Investopedia
Jan-02-18 08:18AM  3 Best Big Pharma Stocks to Buy for 2018 Motley Fool
07:58AM  The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S Zacks
Dec-29-17 02:43PM  4 Large-Cap Pharma Stocks That Outperformed the S&P This Year Zacks
11:24AM  ETFs with exposure to AbbVie, Inc. : December 29, 2017 Capital Cube
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector LLC. It also has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; Harpoon Therapeutics, Inc.; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM